In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ardelyx nets $64.2mm in its IPO

Executive Summary

Ardelyx Inc. (developing therapies for cardiorenal, gastrointestinal, and metabolic diseases) netted $64.2mm in its initial public offering of 4.93mm common shares (including the overallotment) at $14 each. The company had planned to sell 3.6mm shares priced between $13 and $15 each.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies